{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:51:13Z","timestamp":1771379473082,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["330724"],"award-info":[{"award-number":["330724"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"publisher","award":["210054"],"award-info":[{"award-number":["210054"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.neo.2025.101132","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T22:09:09Z","timestamp":1738879749000},"page":"101132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The Impact of Atorvastatin on Intraprostatic Biomarkers \u2013 Prognostic Value of 3LS-score \u2013 Follow-up of ESTO1-Trial"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-4719","authenticated-orcid":false,"given":"Eemil","family":"Lehtonen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiju","family":"Vertanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heimo","family":"Syv\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2029-6497","authenticated-orcid":false,"given":"Teemu","family":"Tolonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4580-1034","authenticated-orcid":false,"given":"Seppo","family":"Auriola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0435-9613","authenticated-orcid":false,"given":"Teuvo","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-427X","authenticated-orcid":false,"given":"Aino","family":"Siltari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teemu","family":"Murtola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2025.101132_bib0001","unstructured":"Tilastot - Sy\u00f6p\u00e4rekisteri. Accessed September 4, 2022. https:\/\/syoparekisteri.fi\/tilastot\/."},{"issue":"1","key":"10.1016\/j.neo.2025.101132_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"10.1016\/j.neo.2025.101132_bib0003","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.7150\/jca.30731","article-title":"Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients","volume":"10","author":"Lin","year":"2019","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.neo.2025.101132_bib0004","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41391-018-0087-0","article-title":"Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer","volume":"22","author":"Murtola","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.neo.2025.101132_bib0005","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ijc.34621","article-title":"Plasma total cholesterol concentration and risk of higher-grade prostate cancer: A nested case-control study and a dose-response meta-analysis","volume":"153","author":"Liu","year":"2023","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.neo.2025.101132_bib0006","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2741\/4216","article-title":"Physiological and pathological implications of cholesterol","volume":"19","author":"Cortes","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"14","key":"10.1016\/j.neo.2025.101132_bib0007","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.7150\/ijbs.42965","article-title":"Pleiotropic use of Statins as non-lipid-lowering drugs","volume":"16","author":"Zhang","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.neo.2025.101132_bib0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.neo.2025.101132_bib0009","doi-asserted-by":"crossref","first-page":"e39445","DOI":"10.1371\/journal.pone.0039445","article-title":"The importance of LDL and cholesterol metabolism for prostate epithelial cell growth","volume":"7","author":"Murtola","year":"2012","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.neo.2025.101132_bib0010","first-page":"9081","article-title":"Biologic and epidemiologic evidence assessing if statins prevent prostate cancer","volume":"24","author":"Dawe","year":"2017","journal-title":"Can J Urol"},{"issue":"2","key":"10.1016\/j.neo.2025.101132_bib0011","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41391-018-0045-x","article-title":"Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer","volume":"21","author":"Allott","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.neo.2025.101132_bib0012","doi-asserted-by":"crossref","first-page":"e46691","DOI":"10.1371\/journal.pone.0046691","article-title":"Statin use and risk of prostate cancer: a meta-analysis of observational studies","volume":"7","author":"Bansal","year":"2012","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.neo.2025.101132_bib0013","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1940-6207.CAPR-17-0396","article-title":"Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study","volume":"11","author":"Mondul","year":"2018","journal-title":"Cancer Prev Res (Phila Pa)"},{"issue":"12","key":"10.1016\/j.neo.2025.101132_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14122920","article-title":"Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level","volume":"14","author":"Peltomaa","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2025.101132_bib0015","article-title":"Statin use and prostate cancer survival in the finnish randomized study of screening for prostate cancer","author":"Murtola","year":"2016","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.neo.2025.101132_bib0016","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urolonc.2018.11.017","article-title":"The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study","volume":"37","author":"Anderson-Carter","year":"2019","journal-title":"Urol Oncol"},{"issue":"28","key":"10.1016\/j.neo.2025.101132_bib0017","doi-asserted-by":"crossref","first-page":"19861","DOI":"10.18632\/oncotarget.24888","article-title":"Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study","volume":"9","author":"Gordon","year":"2018","journal-title":"Oncotarget"},{"issue":"37","key":"10.1016\/j.neo.2025.101132_bib0018","doi-asserted-by":"crossref","first-page":"14328","DOI":"10.1074\/jbc.RA118.004442","article-title":"Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)","volume":"293","author":"Kong","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neo.2025.101132_bib0019","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2022.04.005","article-title":"Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER","volume":"170","author":"Joshua","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.neo.2025.101132_bib0020","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2018.06.037","article-title":"Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial","volume":"74","author":"Murtola","year":"2018","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.neo.2025.101132_bib0021","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1158\/1078-0432.CCR-21-0480","article-title":"Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial","volume":"27","author":"Jeong","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.neo.2025.101132_bib0022","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41391-020-0221-7","article-title":"A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer","volume":"23","author":"Longo","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.neo.2025.101132_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103432","article-title":"Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial","volume":"68","author":"Raittinen","year":"2021","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.neo.2025.101132_bib0024","doi-asserted-by":"crossref","first-page":"12016","DOI":"10.1038\/s41598-020-68868-5","article-title":"Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer","volume":"10","author":"Raittinen","year":"2020","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.neo.2025.101132_bib0025","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/pros.23863","article-title":"Access and concentrations of atorvastatin in the prostate in men with prostate cancer","volume":"79","author":"Knuuttila","year":"2019","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.neo.2025.101132_bib0026","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/ijc.30903","article-title":"A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer","volume":"141","author":"Lin","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.neo.2025.101132_bib0027","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-022-02298-0","article-title":"Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer","volume":"20","author":"Mak","year":"2022","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.neo.2025.101132_bib0028","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.jsxm.2019.07.001","article-title":"Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study","volume":"16","author":"Siltari","year":"2019","journal-title":"J Sex Med"},{"issue":"14","key":"10.1016\/j.neo.2025.101132_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143537","article-title":"Human prostate tissue micrornas and their predicted target pathways linked to prostate cancer risk factors","volume":"13","author":"Enwald","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.neo.2025.101132_bib0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s10278-007-9090-z","article-title":"The application of JPEG2000 in virtual microscopy","volume":"22","author":"Tuominen","year":"2009","journal-title":"J Digit Imaging"},{"issue":"4","key":"10.1016\/j.neo.2025.101132_bib0031","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/bcr2615","article-title":"ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67","volume":"12","author":"Tuominen","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.neo.2025.101132_bib0032","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1046\/j.1464-410x.2001.02193.x","article-title":"Consensus development of a histopathological classification system for chronic prostatic inflammation","volume":"87","author":"Nickel","year":"2001","journal-title":"BJU Int"},{"issue":"13","key":"10.1016\/j.neo.2025.101132_bib0033","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","article-title":"Clinical pharmacokinetics of atorvastatin","volume":"42","author":"Lennern\u00e4s","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.neo.2025.101132_bib0034","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.neo.2025.101132_bib0035","doi-asserted-by":"crossref","first-page":"10345","DOI":"10.18632\/oncotarget.7213","article-title":"Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2\/PPAR\u03b3-dependent pathway","volume":"7","author":"Walther","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.neo.2025.101132_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054911","article-title":"Simvastatin Improves Benign Prostatic Hyperplasia: Role of Peroxisome-Proliferator-Activated Receptor-\u03b3 and Classic WNT\/\u03b2-Catenin Pathway","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.neo.2025.101132_bib0037","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/pcan.2015.58","article-title":"Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis","volume":"19","author":"Raval","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.neo.2025.101132_bib0038","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/annonc\/mdt077","article-title":"Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis","volume":"24","author":"Park","year":"2013","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.neo.2025.101132_bib0039","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-21-1891","article-title":"Statins for prostate cancer: when and how much?","volume":"27","author":"Murtola","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.neo.2025.101132_bib0040","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41391-021-00338-z","article-title":"Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer","volume":"24","author":"Lin","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"19","key":"10.1016\/j.neo.2025.101132_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194792","article-title":"Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin","volume":"14","author":"Mak","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7231","key":"10.1016\/j.neo.2025.101132_bib0042","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T23:19:49Z","timestamp":1740784789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"alternative-id":["S1476558625000119"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101132","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Atorvastatin on Intraprostatic Biomarkers \u2013 Prognostic Value of 3LS-score \u2013 Follow-up of ESTO1-Trial","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101132"}}